Viral hepatitis B and C killed an estimated 1.3 million people in 2024, mostly from cirrhosis and primary liver cancer. HBV alone accounted for about 1.1 million of those deaths, a 17% rise since 2015, even as vaccines and antivirals sit ready.
The numbers expose a slow-motion reckoning. Hundreds of millions live with chronic infection, yet diagnosis and treatment coverage stay stubbornly low. The liver keeps absorbing silent damage until the damage is hard to reverse.
The Scale Behind the Latest Death Toll
WHO’s Global Hepatitis Report 2026 puts the 2024 picture in stark terms. Roughly 240 million people lived with chronic hepatitis B and 47 million with hepatitis C. New infections still numbered about 1.8 million combined.
- 1.3 million total deaths from B- and C-related cirrhosis and liver cancer in 2024
- 1.1 million of those from chronic HBV, up 17% since 2015
- About 240,000 from HCV, down 12% over the same period
- Fewer than 5% of people with chronic HBV receiving antiviral treatment
Just 10 countries accounted for 69% of HBV-related deaths. The African and Western Pacific regions carried three-quarters of that load. HCV deaths spread more widely, yet treatment access still left 11 million already-diagnosed people untreated.
| Metric (2024) | Hepatitis B | Hepatitis C |
|---|---|---|
| People living with chronic infection | 240 million | 47 million |
| Deaths | 1.1 million | ~240,000 |
| Diagnosed share | 27% | 36% |
| On treatment (approx.) | <5% | 20% of eligible since 2015 |
These figures come straight from the less than 5% of chronic HBV on treatment data and companion fact sheets. The gap between available tools and actual reach is the core problem.
The imbalance is structural. Chronic HBV outnumbers chronic HCV by roughly five to one, and its death toll is climbing while HCV deaths ease. That contrast shapes every later decision about testing, vaccination and drug supply.
How Silent Damage Builds Over Years
Chronic hepatitis B and C often produce few or no early symptoms. Fatigue, loss of appetite, nausea, abdominal discomfort, dark urine, jaundice, weight loss or leg and abdominal swelling can appear only after substantial scarring has set in.
Ongoing inflammation drives a clear sequence. First fibrosis (scar tissue builds). Then cirrhosis (severe scarring that disrupts liver function). Then liver failure or hepatocellular carcinoma, the most common primary liver cancer. Extra-hepatic effects can include reduced stamina, concentration problems and lower everyday productivity.
For chronic HCV, WHO notes a 15% to 30% risk of cirrhosis within 20 years. CDC clinical guidance places the cirrhosis range for untreated chronic infection at 5%-25% develop cirrhosis over 10-20 years, with a 1%-4% annual HCC risk once cirrhosis is present. For HBV, lifetime risk of cirrhosis, liver failure or HCC can reach 15-40% in carriers, and up to 25% lifetime liver-cancer risk for those infected at birth without intervention.
- Chronic infection phase, virus persists, often asymptomatic for years or decades
- Fibrosis, progressive scarring begins under ongoing inflammation
- Cirrhosis, advanced scarring impairs blood flow and function
- Decompensation or HCC, liver failure symptoms or cancer appear
Stigma still keeps many from testing. That delay turns a manageable infection into irreversible harm for some.
The long asymptomatic window is what makes the coverage gap so costly. People feel well while scarring advances. By the time symptoms force a clinic visit, the disease has often already moved from fibrosis into cirrhosis or beyond.
Why So Few Reach Treatment
Diagnosis itself lags. Only 27% of people with chronic HBV knew their status in 2024. For HCV the figure sat around 36%. Of those diagnosed with HCV, large numbers still waited for direct-acting antivirals.
Updated WHO 2024 HBV guidelines estimate that more than half of chronic cases may now be treatment-eligible, yet actual uptake stayed under 5%. Tenofovir or entecavir can slow cirrhosis and cut cancer risk, but most people who start therapy need lifelong treatment. For HCV, pan-genotypic DAAs cure more than 95% in 8-12 weeks with few side effects. Prices have fallen dramatically in many lower-income countries, sometimes below US$50 per course, yet systems have not scaled.
Birth-dose hepatitis B vaccination coverage remains especially weak in parts of Africa (only 17% in 2024). Mother-to-child transmission still drives a large share of new chronic cases. Harm-reduction services for people who inject drugs, a major HCV transmission route, also fall far short of targets.
- Low diagnosis rates leave most chronic infections invisible to health systems
- HBV therapy is lifelong, which raises retention and supply demands
- HCV cure courses are short, yet millions already diagnosed remain untreated
- Weak birth-dose coverage keeps feeding new chronic HBV cases
- Harm-reduction gaps sustain HCV transmission among people who inject drugs
Each barrier multiplies the next. Undiagnosed people never reach the pharmacy. Diagnosed people face systems that have not matched the fall in drug prices with simpler pathways into care.
Groups That Face Higher Stakes
Risk is not evenly shared. People with persistently abnormal liver tests, family history of HBV, blood transfusions before routine screening, injection-drug history, occupational blood exposure, or co-infection with HIV carry elevated odds. Infants infected at birth face roughly 95% chance of chronic infection versus under 5% for adult-acquired cases.
Healthcare workers, migrants from high-prevalence regions, men who have sex with men, people in prisons and those with multiple partners appear repeatedly in testing recommendations. In high-burden settings WHO urges broader adult testing. In lower-prevalence places the focus stays on risk groups and all adults at least once, plus every pregnancy.
Regional concentration matters. Western Pacific and African regions hold the bulk of chronic HBV. Eastern Mediterranean carries a heavy HCV share. Ten countries dominate global HBV mortality. Without targeted scale-up, the next decade’s cancer and failure cases will cluster in the same places.
The infant pathway deserves special weight. A 95% chronicity rate after birth infection locks in decades of future cirrhosis and cancer risk. Adult infection, by contrast, usually clears. That single difference explains why birth-dose gaps in Africa translate so directly into later death tolls.
What Already Works When It Reaches People
Hepatitis A and B vaccines remain highly effective. The birth-dose plus subsequent doses for HBV offers near-100% protection and lasts decades. No HCV vaccine exists yet, so prevention rests on safe injections, screened blood, harm reduction and barrier methods.
For those already infected, antivirals change the trajectory. HBV therapy slows fibrosis and reduces HCC incidence. HCV cure eliminates the virus and sharply lowers later risk of cirrhosis progression and cancer. People with chronic HBV or established cirrhosis need regular surveillance: abdominal ultrasound with or without AFP blood testing, following current guidelines.
These measures mirror the logic behind routine screening programs that catch disease early. Waiting for symptoms fails because symptoms arrive late.
What We Know
- Effective vaccines for A and B, curative DAAs for C, and lifelong suppressors for B already exist
- Early treatment demonstrably cuts cirrhosis and HCC rates
- Most new chronic HBV cases still arise from perinatal or early-childhood infection in under-vaccinated areas
What’s Still Missing at Scale
- Diagnosis above the current 27% (HBV) and 36% (HCV) levels
- Treatment coverage that matches the 50%+ eligibility under new guidelines
- Birth-dose and harm-reduction programs in the highest-burden regions
Where programs have simplified testing and linked it straight to treatment, coverage has risen. The science is settled. Delivery is the unfinished work.
HBV and HCV Follow Opposite Death Curves
Since 2015 the two viruses have moved in different directions. HBV deaths rose 17% to 1.1 million. HCV deaths fell 12% to about 240,000. The gap in tools helps explain the split.
| Feature | Hepatitis B | Hepatitis C |
|---|---|---|
| Death trend since 2015 | Up 17% | Down 12% |
| Vaccine available | Yes, near-100% protection | None yet |
| Typical treatment goal | Lifelong viral suppression | Cure in 8-12 weeks |
| Cure or control rate on therapy | Slows fibrosis, cuts HCC risk | >95% cure with DAAs |
| 2024 treatment coverage | <5% of chronic cases | 20% of eligible since 2015 |
HCV benefits from a short, curative course whose price has dropped, sometimes below US$50. HBV still requires years of daily pills and continuous clinic contact. That difference makes scale-up harder even when eligibility expands under the 2024 guidelines.
Prevention also diverges. Birth-dose and infant vaccination can nearly eliminate new chronic HBV. HCV still depends on safe blood, sterile injecting equipment and barrier methods. Until a vaccine arrives, every gap in harm reduction keeps feeding new infections.
The result is visible in the mortality data. One virus is slowly yielding where treatment reaches people. The other continues to convert an aging untreated cohort into cirrhosis and cancer.
The Cost of Waiting Another Decade
Under current trajectories the 2030 elimination targets (65% death reduction, 95% incidence cut for chronic HBV) will be missed. WHO states rapid scale-up of testing and treatment is required. Without it the aging cohort of untreated chronic infections will continue converting into cirrhosis and cancer cases.
Direct medical costs climb steeply once decompensation or HCC appears. Indirect costs from lost work days for patients and caregivers add further weight, especially in working-age adults who make up a large share of the chronic population. Countries that have pushed hard (Egypt on HCV, several others on vaccination and simplified care) show elimination is feasible. Most have not yet matched that pace.
The silent years are the trap. By the time jaundice or swelling forces attention, options narrow. The 1.1 million hepatitis B deaths in 2024 already reflect that lag. Closing the coverage gap is the only way to bend the curve before the next cohort reaches the same endpoints.
Where Focused Scale-Up Changes Outcomes
Egypt’s push on HCV and the gains seen where vaccination and simplified care have been prioritized show that elimination is not theoretical. Those examples sit against a global backdrop in which most countries still lag.
Concentration of burden makes targeted action efficient. Ten countries hold 69% of HBV deaths. African and Western Pacific regions together carry three-quarters of the HBV mortality load. Directing diagnostics, birth-dose programs and antiviral supply to those settings moves the global numbers fastest.
For HCV the map is wider, yet the 11 million already-diagnosed but untreated people form a clear queue. Short courses and lower prices remove the old cost argument. What remains is linkage: testing that leads promptly to a prescription and follow-up that confirms cure.
World Hepatitis Day 2026 simply put fresh numbers on a long-known failure. The tools work. The reach does not. That gap is now measured in preventable funerals.
Frequently Asked Questions
What is the difference in transmission between hepatitis A/E and B/C/D?
Hepatitis A and E spread mainly through contaminated food or water and usually cause short-term acute illness that resolves. B, C and D (which needs B) spread through blood and body fluids, can become chronic, and drive most long-term liver damage and cancer risk.
How high is the lifetime risk of serious liver disease for untreated chronic hepatitis B?
Carriers face a 15-40% lifetime risk of developing cirrhosis, liver failure or hepatocellular carcinoma. Those infected at birth without later treatment can reach up to 25% lifetime liver-cancer risk; annual HCC incidence is under 1% without cirrhosis and 2-4% with it.
Who should get regular liver-cancer surveillance if they have chronic hepatitis?
People with chronic hepatitis B or any form of cirrhosis should undergo abdominal ultrasound every six months, with or without alpha-fetoprotein blood testing, according to current clinical guidelines. This catches HCC earlier when treatment options remain broader.
Can hepatitis C be cured and how long does treatment take?
Yes. Pan-genotypic direct-acting antivirals cure more than 95% of cases. A typical oral course lasts 8-12 weeks (sometimes up to 24 with cirrhosis) with minimal side effects and is now available at low cost in many countries.
Why does birth-dose hepatitis B vaccination matter so much?
Infection in infancy leads to chronic carriage in about 95% of cases versus under 5% for adult infection. Timely birth dose plus follow-up doses cuts that pathway sharply; coverage still sits at only 17% in the WHO African Region, where most new chronic infections occur.
Disclaimer: This article is for general information only and is not medical advice. Consult a qualified healthcare professional for personal diagnosis, testing or treatment decisions.
